Peptide and lipid growth factors decrease cis-diamminedichloroplatinum- induced cell death in human ovarian cancer cells

Clinical Cancer Research

Volumn 2, Issue 8, 1996, Pages 1307-1313

  Frankel, Andrea ^b,c   Mills, Gordon B ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; LYSOPHOSPHATIDIC ACID;

APOPTOSIS; ARTICLE; ASCITES FLUID; CANCER CELL; CANCER SURVIVAL; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMING UNIT; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; KILLER CELL; OVARY CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL SURVIVAL; CISPLATIN; DNA FRAGMENTATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; OVARIAN NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0029781344     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. NIH Consensus Conference. Ovarian cancer: screening, treatment and follow-up NIH consensus development panel on ovarian cancer. JAMA, 273: 491-497, 1995.
2. Cannistra, S. A. Cancer of the ovary. N. Engl. J Med., 329: 1550-1559, 1993
3. Hoskins, P. J. Treatment of advanced epithelial ovarian cancer: past, present and future. Crit. Rev. Oncol. Hematol., 20: 41-59, 1995.
4. Qazi, F., and McGuire W. P. The treatment of epithelial ovarian cancer. CA Cancer J. Clin., 45: 88-101, 1995.
5. Kohn, E. C., Sarosy, G., Bicher, A., Link, C., Christian, M., Steinberg, S. M., Rothenberg, M., Adamo, D. O., Davis, P., Ognibene, F. P., Cunnion, R. E., and Reed, E. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J. Natl. Cancer Inst., 86: 18-24, 1994.
6. Raff, M. C. Social controls on cell survival and cell death. Nature (Lond.), 356: 397-400, 1992.
7. Jacobson, M. D., Burne, J. F., and Raff, M. C. Programmed cell death and bcl-2 protection in the absence of a nucleus. EMBO J., 13: 1899-1910, 1994.
8. Wyllie, A. H., Kerr, J. F. R., and Currie, A. R. Cell death: the significance of apoptosis. Int. Rev. Cytol., 68: 251-301, 1980.
9. Arends, M. J., and Wyllie, A. H. Apoptosis: mechanisms and roles in pathology. Int. Rev. Exp Pathol., 32: 223-254, 1991.
10. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science (Washington DC), 264: 1456-1462, 1995.
11. Wyllie, A. H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (Lond.), 284: 555-556, 1980.
12. Roy, C. Brown, D. L., Little, J. E., Valentine, B. K., Walker, P. R., Sikorska, M., Leblanc, J., and Chaly, N. The topoisomerase II inhibitor teniposide (VM-26) induces apoptosis in unstimulated mature murine lymphocytes. Exp. Cell Res , 200: 416-424, 1992.
13. Cohen, J. J., Duke, R. C., Fadok, V. A., and Sellins, K. S. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol., 10: 267-293, 1992.
14. Ormerod, M. G., O'Neill, C. F., Robertson, D., and Harrap, K. R. Cis-DDP induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA. Exp. Cell Res., 211: 231-237, 1994.
15. Oberhammer, F., Wilson, J. W., Dive, C., Morris, I. D., Hickman, J. A., Wakeling, A. E., Walker, P. R., and Sikorska, M. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J., 12: 3679-3684, 1993.
16. Cohen, G. M., Sun, X. M., Snowden, R. T., Dinsdale, D.. and Skilleter, D. N. Key morphological features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem. J., 286: 331-334, 1992.
17. Berchuck, A., Olt, G. J., Everitt, L., Soisson, A., Bast, R., and Boyer, C. M. The role of peptide growth factors in epithelial ovarian cancer. Obstet. Gynecol., 75: 255-262, 1990.
18. Mills, G., Hashimoto, S., Hurteau, J., Campbell, S., Rubin, L., and Shaw, P. Role of growth factors: their receptors and signalling pathways in the diagnosis, prognosis, follow-up and therapy of ovarian cancer. Diagn. Oncol., 2: 39-54, 1992.
19. Barry, M. A., Behnke, C. A., and Eastman, A. Activation of programmed cell death (apoptosis) by cis-DDP, other anti-cancer drugs, toxins, and hyperthermia. Biochem. Pharmacol., 40: 2353-2362, 1990.
20. Sorensen, C. M., Barry, M. A., and Eastman, A. Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cis-DDP. J. Natl. Cancer Inst., 82: 749-755, 1990.
21. Ormerod, M. G., Orr, R. M., and Peacock, J. H. The role of apoptosis in cell killing by cis-DDP: a flow-cytometric study. Br. J. Cancer, 69: 93-100, 1994.
22. Evans, D. L., and Dive, C. Effects of cis-DDP on the induction of apoptosis in proliferating hepatoma cells and non-proliferating immature thymocytes. Cancer Res., 53: 2133-2139, 1993.
23. Han, I., Ling, Y. H., Khokhar, A., and Perez-Soler, R. Cell death and DNA fragmentation induced by liposomal platinum (II) complex L-NDDP in A2780 and A2780/PDD cells. Anticancer Res., 14: 421-426, 1994.
24. Shi, Y., Frankel, A., Radvanyi, L. G., Penn, L. Z., Miller, R. G., and Mills, G. Rapamycin enhances apoptosis and increases sensitivity to Cis-DDP in vitro. Cancer Res., 55: 1982-1988, 1995
25. Hickman, J. A. Apoptosis induced by anti-cancer drugs. Cancer Metastasis Rev., 11: 121-139, 1992.
26. Dive, C., and Hickman, J. A Drug-target interactions only the first step in the commitment to a programmed cell death? Br. J. Cancer, 64: 192-196, 1991.
27. Havrilesky, L. J., Elbendary, A., Hurteau, J., Whitaker, R., Rodriguez, G., and Berchuck, A. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet. Gynecol., 85: 1007-1010, 1995.
28. Broxterman, H. J., Sprenkels-Schotte, C., Englen. P., Leyva, A., and Pinedo, H. Analysis of human ascites effect on clonogenic growth of human tumor cell lines and NRK-49F cells in soft agar. Int. J. Cell Cloning, 5: 158-169, 1987.
29. Mills, G. B, May, C., McGill, M., Roifman, C. M., and Mellors, A. A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res., 48: 1066-1071, 1988.
30. Mills, G. B, May, C., Hill, M., Campbell, S., Shaw, P., and Marks, A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin. Invest., 86: 851-855, 1990.
31. Wilson, A. P., Fox, H., Scott, I. V., Lee, H., Dent, M., and Golding, P. A comparison of the growth promoting properties of ascitic fluids, cyst fluids and peritoneal fluids from patients with ovarian tumours. Br. J. Cancer, 63: 102-108, 1991.
32. Xu, Y , Gaudette, D., Boynton, J. D., Frankel, A., Fang. X-J., Sharma, A., Hurteau, J., Casey G., Goodbody, A., Mellors, A., Holub, B., and Mills, G. B. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients Clin. Cancer Res., 1: 1223-1232, 1995.
33. Van Corven, E. J., Groenink, A., Jalink, K., Eichholtz, T., and Moolenaar, W. H. Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathway mediated by G proteins. Cell, 59: 45-54, 1989.
34. Van Corven, E. J., Van Rijswijk, A., Jalink, K., and van Der Bend, R. L., vanBlitterswijk, W. J. and Moolenaar, W. H. Mitogenic action of lysophosphatidic acid and phosphatidic acid on fibroblasts. Biochem. J., 281: 163-169, 1992.
35. Johnson, R. A., and Toews, M. L. Protein kinase C activators sensitize cyclic AMP accumulation by intact 1321N1 human astrocytoma cells. Mol. Pharmacol., 37: 296-303, 1990.
36. Watson, S. P., McConnell, R. T., and Lapetina, E. G. Decanoyl lysophosphatidic acid induces platelet aggregation through an extracellular action. Evidence against a second messenger role of lysophosphatidic acid. Biochem. J., 232: 61-66, 1985.
37. Gerrard, J. M., and Robinson, P. Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin. Biochim. Biophys. Acta, 101: 282-285, 1989.
38. Eichholtz, T., Jalink, K., Frhrefort, M., and Moolenaar, W. H. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem. J , 291: 677-680, 1993
39. Moolenaar, W H. LPA: a novel lipid mediator with diverse biological actions. Trends Cell Biol., 4: 213-218, 1994.
40. Kreps, D. M., Whittle, S. M., Hoffman, J. M., and Toews. M. L. Lysophosphatidic acid mimics serum-induced sensitization of cyclic AMP accumulation. FASEB J., 7: 1376-1380, 1993.
41. Proll, M. A., Clark, R. B., and Butcher, R. W. Phosphatidate and monooleylphosphatidate inhibition of fibroblast adenylate cyclase is mediated by the inhibitory coupling protein Ni. Mol. Pharmacol., 28: 331-337, 1985.
42. Inamura, F., Horai, T., Mukai, M., Shinkai, K, Sawada, M., and Akedo, H. Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D. Biochem. Biophys. Res. Commun., 193: 497-503, 1993.
43. Berchuck, A., Rodriguez, G. C., Kamel, A., Dodge, R., Soper, J. T., Clarke-Pearson, D. L , and Bast, R. C. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. Am. J. Obstet. Gynecol., 164, 669-674, 1991.
44. Morishige, K., Kurachi, H., Amemiya, K., Fujita, Y., Yamamoto, T., Miyake, A., and Tanizawa, O. Evidence for the involvement of transforming growth factor α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res., 51: 5322-5328, 1991.
45. Kurachi, H., Morishige, K., Amemiya, K., Adachi, H., Hirota, K., Miyake, A., and Tanizawa, O. Importance of transforming growth factor α/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vivo. Cancer Res., 51: 5956-5959, 1991.
46. Buick, R. N., Pullano, R., and Trent, J. M. Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res., 45 3668-3676, 1985.
47. Mosmann, T. Rapid colorimetric assay for cellular growth and survival. J. Immunol. Methods, 65: 55-63, 1983.
48. Brunk, C. F., Jones, K., and James, T. W Assay for nanogram quantities of DNA in cellular homogenates. Anal. Biochem., 92: 497-500, 1979.
49. Brunk, C. F., and James, T. W. Intracellular and in vitro fluorescence of the DNA specific probe: 4′6-diamidino-2-phenylindole (DAPI). J. Cell Biol., 75: 136a, 1977.
50. Sinha, S., Marshall, C., and Neal, G. γ-glutamyltranspeptidase and the Ras-induced transformation of a rat liver cell line. Cancer Res., 46: 1440-1445, 1986.
51. Macpherson, I., and Montagnier, L. Agar suspension cultures for the selective assay of cells transformed by polyoma virus. Virology, 23: 291-294, 1964.
52. Otani, H., Erdos, M., and Leonard, J Tyrosine kinases(s) regulate apoptosis and bcl-2 expression in a growth factor-dependent cell line. J. Biol. Chem., 268: 22733-22736, 1993.
53. Lang, T., Daxenbichler, D., and Marth, C. Effects of cytostatic agents on the expression of epidermal growth factor receptor in ovarian cancer cells. Anticancer Res., 14: 1871-1874, 1994.
54. Piazza, G., Ritter, J., and Baracka, C. Lysophosphatidic acid induction of transforming growth factors α and β: modulation of proliferation and differentiation in cultured human keratinocytes and mouse skin. Exp. Cell Res., 216: 51-64, 1995.
55. Daub, H., Weiss, F. U., Wallasch, C , and Ullrich, A. Role of transactivation of the EGF receptor in signalling G-protein coupled receptors. Nature (Lond.), 379: 557-560, 1996.
56. Fan, Z., Baselga, J., Masui, H., and Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatin on well established A431 cell xenografts. Cancer Res., 53: 4637-4642, 1993.
57. Leek, R., Kaklamanis, L., Pezzella, F., Gatter, K., and Harris, A. Bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumors and in situ cancer. Br. J. Cancer, 69: 135-139, 1994.
58. Andrews, P. A., and Howell, S. B. Cellular pharmacology of cis-DDP: perspectives on mechanisms of acquired resistance. Cancer Cells. 2: 35-43, 1990.
59. Christen, R. D., Hom, D K., Porter, D. C , Andrews, P. A., Macleod, C. L., Hafstrom, L., and Howell, S. B. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cis-DDP. J. Clin Invest , 86: 1632-1640. 1990.